首页> 美国卫生研究院文献>NPG Open Access >Optimal convection volume for improving patient outcomes in an international incident dialysis cohort treated with online hemodiafiltration
【2h】

Optimal convection volume for improving patient outcomes in an international incident dialysis cohort treated with online hemodiafiltration

机译:在通过在线血液透析滤过治疗的国际事件透析队列中最佳对流量可改善患者预后

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Online hemodiafiltration (OL-HDF), the most efficient renal replacement therapy, enables enhanced removal of small and large uremic toxins by combining diffusive and convective solute transport. Randomized controlled trials on prevalent chronic kidney disease (CKD) patients showed improved patient survival with high-volume OL-HDF, underlining the effect of convection volume (CV). This retrospective international study was conducted in a large cohort of incident CKD patients to determine the CV threshold and range associated with survival advantage. Data were extracted from a cohort of adult CKD patients treated by post-dilution OL-HDF over a 101-month period. In total, 2293 patients with a minimum of 2 years of follow-up were analyzed using advanced statistical tools, including cubic spline analyses for determination of the CV range over which a survival increase was observed. The relative survival rate of OL-HDF patients, adjusted for age, gender, comorbidities, vascular access, albumin, C-reactive protein, and dialysis dose, was found to increase at about 55 l/week of CV and to stay increased up to about 75 l/week. Similar analysis of pre-dialysis β2-microglobin (marker of middle-molecule uremic toxins) concentrations found a nearly linear decrease in marker concentration as CV increased from 40 to 75 l/week. Analysis of log C-reactive protein levels showed a decrease over the same CV range. Thus, a convection dose target based on convection volume should be considered and needs to be confirmed by prospective trials as a new determinant of dialysis adequacy.
机译:在线血液透析滤过(OL-HDF)是最有效的肾脏替代疗法,它通过结合扩散和对流溶质转运来增强去除大小尿毒症毒素的能力。对流行的慢性肾脏病(CKD)患者的随机对照试验表明,大剂量OL-HDF可以改善患者生存率,这突出了对流量(CV)的影响。这项回顾性国际研究在一大批CKD突发事件患者中进行,以确定与生存优势相关的CV阈值和范围。数据是从101个月期间通过稀释后OL-HDF治疗的成年CKD患者队列中提取的。总共,使用先进的统计工具对2293例至少随访2年的患者进行了分析,包括三次样条分析,用于确定观察到生存率增加的CV范围。根据年龄,性别,合并症,血管通路,白蛋白,C反应蛋白和透析剂量进行调整的OL-HDF患者的相对存活率在CV约55微升/周的情况下增加,并且一直保持到大约每周75升。透析前β2-微球蛋白(中分子尿毒症毒素的标志物)浓度的类似分析发现,随着CV从40增加到75μl/周,标志物浓度几乎呈线性下降。对数C反应蛋白水平的分析表明,在相同的CV范围内下降。因此,应该考虑基于对流量的对流剂量目标,并且需要通过前瞻性试验来确定其作为透析充分性的新决定因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号